Nityr (Nitisinone) Patent Expiration, LOE Window & CMS Spending

Nityr (Nitisinone) by Cycle: FDA Orange Book LOE 2035-01-05, 3 AB generics, $20.0M 2024 CMS Part D & Medicaid spend, and $89,106 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCycle
FDA Application & PathwayN209449 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-01-05
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$20.0M
2024 Medicare Part D Spend$41K
2024 Medicaid Spend$20.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($89,106 intro WAC)